TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $37.67 Average Price Target from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have received an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $40.67.

Several brokerages have recently commented on TGTX. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. B. Riley increased their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright increased their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $35.00 on Monday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics has a one year low of $12.32 and a one year high of $36.84. The company’s 50-day simple moving average is $26.00 and its 200-day simple moving average is $21.95. The stock has a market capitalization of $5.45 billion, a price-to-earnings ratio of -342.57 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same period in the previous year, the business posted $0.73 EPS. The business’s revenue for the quarter was down 49.4% on a year-over-year basis. Equities analysts anticipate that TG Therapeutics will post 0.17 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in TGTX. State Street Corp increased its stake in shares of TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after purchasing an additional 2,398,015 shares during the period. Marshall Wace LLP bought a new position in shares of TG Therapeutics in the second quarter valued at approximately $36,501,000. Principal Financial Group Inc. boosted its holdings in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after acquiring an additional 725,371 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of TG Therapeutics in the second quarter valued at approximately $10,423,000. Finally, Assenagon Asset Management S.A. bought a new position in shares of TG Therapeutics in the second quarter valued at approximately $8,698,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.